SOURCE: Nuvilex, Inc.

Nuvilex, Inc.

August 07, 2013 08:30 ET

Nuvilex, Inc. to Control 2 of the Big 3 Multi Billion Dollar Drug Markets With Technology

NEW YORK, NY--(Marketwired - Aug 7, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is methodically laying the foundation today for what should be a very busy and promising future tomorrow. After making a blockbuster deal to acquire Bio Blue Bird and its worldwide licenses associated with the live-cell encapsulation platform technology to develop treatments for all cancer types, Nuvilex announced this week that it now intends to do the same thing with diabetes. 

When Nuvilex pulls off this acquisition, it will control 2 of the big 3 multi-billion dollar drug markets -- cancer and diabetes -- with regard to the use of this unique and proprietary live-cell encapsulation technology. 

The company's intent is to capture the exclusive worldwide rights for the use of the live-cell encapsulation technology for the development of treatments for diabetes from SG Austria Pte. Ltd. According to the American Diabetes Association, in the U.S. alone, $176 billion is spent annually on medical costs associated with diabetes with over $22 billion of that being spent on treatments for the disease. 

Recent estimates project that as many as one in three American adults will have diabetes by 2050. With these numbers growing dramatically, so too are the costs for treatment. Nuvilex said it expects to close this deal at the end of October.

By 2020, the annual market for diabetes medicines is projected to reach $65 billion worldwide. Statistics released by the International Diabetes Federation state that over 370 million people around the world have been diagnosed with diabetes and almost another 190 million remain undiagnosed -- leaving many millions susceptible to the debilitating, and even deadly, complications associated with this disease. 

Continue reading this article at www.stockmarketmediagroup.com/features.

About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors. For more information: www.stockmarketmediagroup.com

This article is the opinion of Stock Market Media Group and was written based upon publicly available information. Nuvilex has not endorsed or compensated Stock Market Media Group for this article.

Contact Information